Cupertino, California, and Seoul, South Korea – June 10, 2025 – CARPL, a California-based vendor-neutral AI platform, and PurpleAI, a South Korea-based medical AI company focused exclusively on cerebrovascular diseases, announced a strategic partnership to deliver PurpleAI’s FDA-cleared Hyper Insight - ICH™ solution through the CARPL platform. The collaboration aims to accelerate the adoption of AI-powered tools for the timely and accurate detection of intracranial hemorrhage in emergency settings.
“In our endeavor to simplify how health systems explore, validate, and adopt AI, Hyper Insight - ICH™, now being available through the CARPL.ai Platform, gives users a high-impact application seamlessly accessible through our interface,” said Dhruv Sahai, COO of CARPL.ai.
CARPL provides healthcare professionals with access to over 175 radiology AI applications from 75+ vendors through a single integration point. Designed to streamline radiology workflows, CARPL enables the discovery, validation, and deployment of AI at scale. With the addition of Hyper Insight - ICH™, CARPL enhances its portfolio with a high-performance solution that identifies suspected intracranial haemorrhagehemorrhage on non-contrast head CT scans within seconds, supporting faster triage and improved clinical decision-making.
“This partnership reinforces our mission to bring high-impact AI to the frontlines. Hyper Insight - ICH™ supports faster triage and better decisions, all integrated into existing workflows through CARPL’s zero-disruption platform,” said Vidur Mahajan, CEO of CARPL.ai.
PurpleAI’s Hyper Insight - ICH™ is a cloud-based Software-as-a-Medical-Device (SaMD) that received FDA 510(k) clearance in July 2024. Designed for emergency department workflows, the solution enables rapid triage by automatically detecting and highlighting potential suspected hemorrhages, helping ER physicians and radiologists prioritize critical cases and reduce diagnostic delays.
"We’re proud to partner with CARPL to expand access to our AI-powered ICH detection tool," said Byungjun Park, CEO of PurpleAI. "Through this integration, we’re bringing our FDA-cleared technology to more healthcare providers, enabling faster and more confident decisions in stroke emergencies."
CARPL.ai is the world's only US-FDA cleared and CE marked vendor-neutral Artificial Intelligence (AI) platform that enables radiologists and researchers to seamlessly access, assess, and integrate radiology AI solutions into their clinical practice. CARPL provides a single user interface, a single data channel, and a single procurement channel for the testing, deployment, and monitoring of AI solutions in clinical radiology workflows. We are the world’s largest radiology AI marketplace, offering over 175 applications from 75+ AI vendors. The platform integrates deeply with leading PACS systems, including Agfa HealthCare, DeepHealth, Intelerad, Ramsoft, among others, ensuring end-to-end interoperability across imaging environments. From research validation to clinical deployment, CARPL.ai serves as the orchestration layer for responsible, scalable AI adoption in radiology.
PurpleAI, a spin-off from SK Group, is a South Korea-based medical AI company dedicated exclusively to cerebrovascular diseases. The company’s FDA-cleared clinical decision support software delivers best-in-class performance for brain hemorrhage detection. Purpose-built for community hospital ERs and telestroke providers, PurpleAI integrates seamlessly into existing workflows to enhance clinical accuracy and improve patient outcomes in stroke care.
Media Contacts
CARPL
Shruti Singhal
shruti.singhal@carpl.ai
PurpleAI
Honggyu Lim
yhg@purple-ai.co
